Recent News AGN.c AGNPF (a clinical stage Canadian pharmaceutical development company) announced Wednesday they’ve been invited to present the results from its Phase 2a Study of NP-120 for idiopathic pulmonary fibrosis and Chronic Cough, at the 9th American Cough Conference in June, 2023.
The conference is the world's leading educational meeting for health care professionals involved in the research and management of patients with cough.
With the most recent update from the Phase 2a Study showing Ifenprodil was much more effective at reducing cough in patients than initially reported, it’s great to see that AGN will be able to show this off at such a profound conference in the space.
https://ir.algernonpharmaceuticals.com/news-events/press-releases/detail/157/algernon-pharmaceuticals-invited-to-present-phase-2-ipf-and